CClinicalTrials.gg
WithdrawnNCT03213600NSOCOGUpdated Apr 22, 2019

Neurostimulation-enhanced Behavioral Remediation of Social Cognition in Schizophrenia

An interventional study of transcranial Direct Current Stimulation tDCS in Behaviors and Mental Disorders, sponsored by Hôpital le Vinatier. Withdrawn at 1 site in France. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-04-22.

Sponsored by Hôpital le Vinatier · Not applicable, Interventional, and Basic science

Why this study was withdrawn
One of the investigators went abroad
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Social cognition concerns the understanding of how people think about others and how that, in turn, influences our behavior, feelings, and social interactions. schizophrenia social-cognitive impairment is profound (effect size D>1.2), medication resistant and critically limits functional well-being . Social cognition involves complex patterns of coordinated activity within numerous cortical and subcortical networks, making it a difficult target for clinical neuroscience investigation. Yet, prior research demonstrates that sensory-perceptual dysfunction in schizophrenia can upwardly generalize into higher-order social-cognitive impairment making perception a tractable and fruitful approach for studying social cognition in schizophrenia. Here, the investigators explore how distortions in perception of temporal coincidence can contribute to the aberrant inferences of physical causation and social agency.

Read the detailed description

Social cognitive deficits in these patients are robust and hinder their ability to maintain gainful employment as well as forge and sustain meaningful social relationships. Current antipsychotic medications are largely ineffective in treating these symptoms. The proposed protocol aims at utilizing Noninvasive Brain Stimulation (NIBS) and cognitive behavioral training to enhance core perceptual impairment in marking time that may contribute to both social and nonsocial cognitive dysfunction in schizophrenia.

Cognitive behavioral training along the line investigators propose has no reported adverse effects.The transdirect current stimulation (tDCS) is a very safe method with encouraging results in previous works in which no severe adverse events where found. There are a few minor side effects including skin irritation, a phosphene at the start of stimulation, nausea, headache, dizziness, and itching under the electrode. A recent study of over 500 subjects using the currently accepted protocol reported only a slight skin irritation and a phosphene as side effects. Patients can benefit from a significant improvement of invalidant symptoms but also of their quality of life. To ensure safety, patients will be accompanied throughout the protocol by professionals trained in the management of their disease. Besides the protocol procedure, patients will be supported, in all centers, according to the international recommendations in terms of safety and practice. Patients receiving placebo procedure after randomization will pursue pharmacological treatment and usual health care.

02

Conditions studied

  • Behaviors and Mental Disorders
03

In context

Schizophrenia

3,471 studies on the registry are indexed under Schizophrenia; 472 are open to participants now.

Browse Schizophrenia studies →

Lead sponsor

Hôpital le Vinatier is the lead sponsor of 106 studies on the registry; 41 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • be between 18 and 45-years-old
  • have normal hearing assessed by the Five-minute hearing test
  • have French as a first language
  • be able to provide written informed consent
  • be right handed as measured by the Edinburgh handedness scale
  • covered by, or having the right to Social Security
  • informed consent signed
  • patients with diagnosis of schizoprenia or schizoaffective disorder-depressive type as determined by the SCID Diagnostic Interview for DSM-V and administered by a clinician
  • clinically stable and on a stable medication regiment for the past 3 months

Exclusion criteria

Exclusion Criteria:

  • significant medical or neurological illness or history of fetal alcohol exposure that may increase risks of the study, significantly affect brain function, or impede participation
  • substance dependence (except nicotine) or abuse not in remission within the past six months or recent use presenting the possibility of acute intoxication or withdrawal
  • a history of any Axis I psychiatric disorder except those required in the inclusion criteria, any history of pervasive developmental disorder or mental retardation
  • for Visit 3: If participating in tCDS Contraindications for tDCS (pacemaker or brain stimulator) and/or MRI (neurologic stimulator, pacemaker, cardiac defibrillator, cardiac prosthesis, vascular prosthesis, intracranial clips or clamps, cerebrospinal fluid derivation, metallic splinters in the eyes)
  • patients under curatorship/guardianship and whose clinical condition requires inpatient procedure under constraint
  • healthy controls must not be currently using psychoactive médications or have a first-degree relative with a psychotic disorder
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    transcranial Direct Current Stimulation ( tDCS )

    Intensity : 1,5mA Duration : 20 minutes stimulation over frontal (F3/F4) electrodes

    Device: transcranial Direct Current Stimulation tDCS

  • Sham comparator
    transcranial Direct Current Stimulation ( tDCS)

    Intensity : 1,5mA Duration : 20 minutes stimulation over parietal(CP3 CP4) electrodes

    Device: transcranial Direct Current Stimulation tDCS

Interventions

  • Devicetranscranial Direct Current Stimulation tDCS

    75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)

06

What researchers measure

Primary outcomes

  1. Causation Task - testing time based causal judgments

    Primary metric: threshold defined as the smallest time difference (in 16.7ms increments) at which subject judge ball movement "B" to be caused by the impact of ball "A" 75% of the time.

    Time frame: 3 months

  2. Triangle Task - measuring the extent to which temporal coincidence is used to infer causality in a social situation

    Primary metric: threshold of tolerated relational time delay (levels in 16.7ms increments) between interacting visual figures (i.e triangles), under which participants reliably (at 75%) perceive social agency or social interactions.

    Time frame: 3 months

Secondary outcomes

  1. EEG Task 1, Time visual oddball task - for measuring electrophysiological markers of active temporal (time) deviance detection

    Primary metric: Mismatch negativity in the event related potentials of electrodes over the visual cortex with typical latency of 150-250ms after the onset of the deviant stimuli

    Time frame: 3 months

  2. EEG Task 2, Covert visual simultaneity task - an exploratory task designed to model the visual Simultaneity behavioral task

    Primary metric: Dependent measure: decibel change in Alpha and Beta power across bellow- threshold and above- threshold conditions

    Time frame: 3 months

  3. Resting state oscillatory structure

    Primary metric: Dependent measure: decibel change in Alpha and Beta power during rest

    Time frame: 3 months

07

Study locations

1 site
  • Hopital Le Vinatier
    Bron, 69678, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03213600
Lead sponsor
Hôpital le Vinatier
Responsible party
Sponsor
First posted
Jul 11, 2017
Start date
Nov 1, 2018 (estimated)
Primary completion
Sep 1, 2019 (estimated)
Completion
Dec 31, 2019 (estimated)
Last update
Apr 22, 2019

Study contacts

POULET EMMANUEL, MD - PhD
principal investigator · CH LE VINATIER

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion